Gyre Therapeutics Files Q3 2024 10-Q

TL;DR

Gyre Therapeutics filed its Q3 2024 10-Q. Financials and operations update.

AI Summary

Gyre Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial performance and business operations, including details on its pharmaceutical preparations and any significant business developments during the quarter. The filing also provides updates on its former names, Catalyst Bioscience, Inc. and Targacept Inc., and its fiscal year end of December 31.

Why It Matters

This filing provides investors with a crucial update on Gyre Therapeutics' financial health and operational progress for the third quarter of 2024, impacting investment decisions.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Gyre Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

• Q3 2024 — Reporting Period (Covers the third quarter of 2024.)
• 2024-09-30 — Period End Date (The end date for the financial reporting period.)
• 2024-11-13 — Filing Date (The date the 10-Q was officially filed with the SEC.)

Key Players & Entities

• GYRE THERAPEUTICS, INC. (company) — Filer
• CATALYST BIOSCIENCES, INC. (company) — Former Company Name
• TARGACEPT INC (company) — Former Company Name
• SINOPHARM GROUP COMPANY LIMITED (company) — Customer
• 20240930 (date) — Reporting Period End Date
• 20241113 (date) — Filing Date

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share GYRE The Nasdaq Capital M

Filing Documents

• gyre-20240930.htm (10-Q) — 2702KB
• gyre-ex3_1.htm (EX-3.1) — 39KB
• gyre-ex31_1.htm (EX-31.1) — 16KB
• gyre-ex31_2.htm (EX-31.2) — 16KB
• gyre-ex32_1.htm (EX-32.1) — 12KB
• gyre-ex32_2.htm (EX-32.2) — 12KB
• 0000950170-24-126306.txt ( ) — 11685KB
• gyre-20240930.xsd (EX-101.SCH) — 1506KB
• gyre-20240930_htm.xml (XML) — 2412KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION 2 Item 1.

Financial Statements

Financial Statements: 2 Condensed Consolidated Balance Sheets as of September 30, 2024 (unaudited) and December 31, 2023 2 Condensed Consolidated Statements of Operations and Comprehensive Income for the three and nine months ended September 30, 2024 and 2023 (unaudited) 3 Condensed Consolidated Statements of Convertible Preferred Stock and Equity for the three and nine months ended September 30, 2024 and 2023 (unaudited) 4 Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2024 and 2023 (unaudited) 5 Notes to the Unaudited Condensed Consolidated Financial Statements 6 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 24 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 37 Item 4.

Controls and Procedures

Controls and Procedures 37

OTHER INFORMATION

PART II. OTHER INFORMATION 38 Item 1.

Legal Proceedings

Legal Proceedings 38 Item 1A.

Risk Factors

Risk Factors 38 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 39 Item 3. Defaults Upon Senior Securities 39 Item 4. Mine Safety Disclosures 39 Item 5. Other Information 39 Item 6. Exhibits 40 Exhibit Index 40

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

FIN ANCIAL STATEMENTS

ITEM 1. FIN ANCIAL STATEMENTS Gyre Therapeutics, Inc. Condensed Consolidat ed Balance Sheets (In thousands, except share and per share amounts) September 30, 2024 December 31, 2023 (Unaudited) Assets Current assets: Cash and cash equivalents $ 15,866 $ 33,509 Short-term bank deposits 9,226 — Accounts and note receivables, net 19,487 15,552 Other receivables from GNI 1,287 1,287 Inventories, net 6,379 4,281 Prepaid assets 1,051 1,547 Other current assets 1,513 1,045 Total current assets 54,809 57,221 Property and equipment, net 24,442 23,288 Long-term receivable from GCBP 4,900 4,722 Intangible assets, net 184 205 Right-of-use assets 1,984 489 Land use rights, net 1,479 1,493 Deferred tax assets 5,161 4,695 Long-term certificates of deposit 29,515 23,431 Other assets, noncurrent 2,766 995 Total assets $ 125,240 $ 116,539 Liabilities, convertible preferred stock, and equity Current liabilities: Accounts payable $ 303 $ 355 Deferred revenue 36 39 Due to related parties 1,288 1,369 CVR excess closing cash payable — 1,085 Accrued expenses and other current liabilities 9,553 11,935 Income tax payable 2,842 5,054 Operating lease liabilities, current 694 210 Total current liabilities 14,716 20,047 Operating lease liabilities, noncurrent 1,101 199 Deferred government grants 185 213 CVR derivative liability, noncurrent 4,900 4,722 Warrant liability, noncurrent 5,862 12,835 Other noncurrent liabilities 2 49 Total liabilities 26,766 38,065 Commitments and Contingencies (Note 12) Convertible Preferred Stock, $ 0.001 par value, 5,000,000 shares authorized; nil shares and 13,151 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively — 64,525 Stockholders' equity: Common stock, $ 0.001 par value, 400,000,000 shares authori

View Full Filing

View this 10-Q filing on SEC EDGAR